Introduction
============

The cardiac risk of starting testosterone replacement therapy (TRT) is controversial. Three recent studies which suggested an increase risk of cardiovascular events following TRT ([@r1]-[@r3]) led to an FDA review and updated labeling that indicates a possible increased risk of heart attacks and strokes following TRT. The methodology and conclusions of these studies have been criticized ([@r4]) and position statements and guidelines from medical societies do not support the FDA's concerns ([@r5]). Nevertheless, concern remains whether TRT can be safely given to men, especially those with cardiac risk factors.

If one accepts the hypothesis that TRT leads to early cardiovascular complications, there must be a mechanism that would lead to myocardial infarction in as early as 3 months. Since TRT does not cause progression of atherosclerotic plaque ([@r6]), the more likely mechanism in this short timeframe would be through worsening of endothelial function ([@r7]). Furthermore, since cardiovascular events are relatively rare following TRT, if endothelial dysfunction were indeed the mechanism linking the two, one would expect a higher incidence of endothelial dysfunction than myocardial infarction. Because of this increased incidence, this may provide a useful surrogate endpoint to more effectively evaluate the effect of TRT on cardiovascular function.

Endothelial cell dysfunction can be measured by assessing peripheral arterial tone and it's response to nitric oxide mediated relaxation induced by ischemia-reperfusion and sheer stress. The EndoPAT-2000 (Itamar Medical, Caesarea, Israel) is a device that non-invasively measures vascular endothelial cell function and arterial stiffness by measuring the peripheral arterial tone of the index finger before and after temporary occlusion of flow with a blood pressure cuff ([@r8]). If indeed TRT leads to increased early cardiac events we hypothesize that institution of TRT would worsen arterial endothelial function as measured by EndoPAT.

Methods
=======

Adult men were consented for this IRB approved study from our Men's Health clinic if they had symptoms of hypogonadism, a total testosterone \<350 ng/dL, and planned to begin TRT. Demographic data was collected including medical comorbidities and starting total testosterone values. The first EndoPAT test was done before starting TRT and the second between 3--6 months later at the first follow-up appointment if the patient was compliant with therapy. Topical gels or Testopel were used for TRT and target testosterone confirmed post therapy.

Men were tested with an EndoPAT-2000 machine according to manufacturer's instructions. Briefly, men sat in a quiet room with a device on both index fingers that measures arterial tone. A blood pressure cuff on the left arm occluded arterial blood flow for 5 minutes and then released. The software then calculated the augmentation index (AI), a measure of arterial stiffness and reactive hyperemia index (RHI), a measure of nitric oxide mediated endothelial vasodilation. Prior studies suggest that a 10% level of day-to-day test variability is expected ([@r9]). Both elevated AI and diminished RHI suggest vascular and endothelial disease.

Changes in continuous variables were assessed with the paired *t*-test and significance set at P\<0.05. Statistical analyses were performed with Prism 5.0 for Macintosh (Graphpad software).

Results
=======

Twenty-three patients were consented with a mean age of 52.7 years (range, 34--68 years). Mean starting testosterone 196.9 ng/dL (range, 35--339 ng/dL). There was a self-reported history of diabetes in four men, hypertension in ten and coronary artery disease in five. At baseline measurement mean RHI was 1.67±0.37 (70% were abnormal) and mean AI was 2.57%±14.0% (39% were abnormal). No patient subsequently developed a clinical cardiac event.

At first clinical follow-up 3--6 months later, 20 patients were compliant with therapy and retested. Mean total testosterone increased from 203 to 511 ng/dL (P\<0.0001) ([*Figure 1*](#f1){ref-type="fig"}). Mean RHI improved from 1.70 to 2.14 (P=0.01) ([*Figure 2*](#f2){ref-type="fig"}). Mean AI improved from 2.9% to −1.75% (P=0.01) ([*Figure 3*](#f3){ref-type="fig"}). In four men RHI was lower than before starting TRT but in each case the decrease was less than the 10% error of the test (range, 1.3--6.3%). No man had worsening of AI.
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Discussion
==========

The cardiovascular risks of TRT remain controversial. Concern initially developed from cardiac outcomes in studies of women. The Women's Health Initiative found a modest increase in cardiovascular events with hormonal replacement; seven additional cardiac heart disease events and eight additional strokes per 10,000 person years ([@r10]).

Following this, a series of studies raised the possibility that TRT might also increase the risk of cardiovascular complications including stroke and myocardial infarction ([@r3]) and other cardiac events ([@r1]). There have been criticisms to the design of these studies ([@r11]), especially since they required significant statistical adjustment to arrive at their conclusions. Additionally these findings were counterintuitive given that TRT is known to improve several risk factors for cardiovascular disease including fasting glucose and waist circumference ([@r12]). Indeed, subsequent studies have shown a reduced risk of myocardial infarction following TRT, this includes a recent study of 83,010 men in a VA study, one of the largest studies on this topic to date ([@r1],[@r13]). Nevertheless, the FDA recently required a labeling change to inform patients of a possible increased risk of heart attack and stroke (<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm436280.htm>).

Part of this controversy is due to the fact that no definite mechanism for testosterone's effect on cardiovascular disease has been discovered. Certainly polycythemia is a possible side effect that can promote thrombosis and fluid retention which can exacerbate severe heart failure, but monitoring for polycythemia is a standard as part of treating patients with testosterone and should be limited in most patients. Atherosclerosis and other traditional risk factors for heart disease are too slow for the time scale suggested by the studies that demonstrate an increase in cardiac events. If indeed TRT increases cardiovascular risk, at least in a subset of patients, we believe an effective surrogate marker would be endothelial dysfunction, especially since cardiovascular events occur so rarely. While this is not a proven mechanism of testosterone's effect on cardiovascular health, we propose that it is one of the most likely mechanisms due to the time course of the proposed increase in cardiovascular events. Abnormal endothelial function as measured by peripheral arterial tone is known to be predictive of late cardiovascular events ([@r14]). Indeed, hypogonadism has already been associated with endothelial dysfunction and cardiovascular risk in men with renal disease ([@r15]). The EndoPAT machine used in this study uses changes in peripheral arterial tone before and after brachial artery occlusion to produce two values: RHI which measures nitric oxide mediated endothelial relaxation (higher is better) and AI which measures arterial stiffness (lower is better) ([@r8]). While few studies have followed patients longitudinally, between day variability of RHI is about 10% ([@r9]).

In our study, both RHI and AI either stayed the same or improved in all patients 3--6 months after starting TRT. As expected, most of the patients with hypogonadism started out with abnormal values (70% abnormal RHI and 39% abnormal AI), confirming a link between hypogonadism and cardiovascular risk ([@r16]). This supports previous data from other studies that demonstrates patients with hypogonadism have increased rates cardiovascular events and death ([@r17]). That endothelial function did not worsen after 3--6 months of therapy does not necessarily suggest ongoing improvement; however the key studies implicating TRT as a cause of increased risk for cardiovascular complications noted those complications as early as 3 months into therapy. Our study shows that endothelial dysfunction, a possible mechanism for such changes does not change in this time period, adding to the data that testosterone therapy does not worsen cardiac function in the short-term.

This represents the first study evaluating the effects of testosterone on endothelial dysfunction as measured by EndoPAT, a proposed mechanism for testosterone's yet unclear effect on cardiovascular health. Limitations of our study include its small size. Despite this, its prospective nature and low number of patients lost to follow-up reinforce the importance of the findings.

Conclusions
===========

We found that endothelial dysfunction does not worsen in patients starting testosterone therapy within the first 3--6 months of therapy. While the full effects of testosterone therapy on the cardiovascular system have not been fully elucidated, this study increases the body of literature that it is safe for use within patients for whom it is clearly indicated.
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